1. Long-Acting Cabotegravir Protects Macaques Against Repeated Penile Simian-Human Immunodeficiency Virus Exposures.
- Author
-
Dobard C, Makarova N, Nishiura K, Dinh C, Holder A, Sterling M, Lipscomb J, Mitchell J, Deyounks F, Garber D, Khalil G, Spreen W, Heneine W, and García-Lerma JG
- Subjects
- Animals, Chemoprevention methods, Disease Models, Animal, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination therapeutic use, HIV Integrase Inhibitors pharmacokinetics, Macaca mulatta, Male, Penis virology, Pre-Exposure Prophylaxis, Pyridones pharmacokinetics, Simian Immunodeficiency Virus metabolism, HIV Integrase Inhibitors administration & dosage, Pyridones administration & dosage, Simian Acquired Immunodeficiency Syndrome prevention & control, Simian Acquired Immunodeficiency Syndrome transmission, Simian Immunodeficiency Virus drug effects
- Abstract
We used a novel penile simian-human immunodeficiency virus (SHIV) transmission model to investigate whether long-acting cabotegravir (CAB LA) prevents penile SHIV acquisition in macaques. Twenty-two macaques were exposed to SHIV via the foreskin and urethra once weekly for 12 weeks. Of these, 6 received human-equivalent doses of CAB LA, 6 received oral emtricitabine/tenofovir disoproxil fumarate, and 10 were untreated. The efficacy of CAB LA was high (94.4%; 95% confidence interval, 58.2%-99.3%) and similar to that seen with oral emtricitabine/tenofovir disoproxil fumarate (94.0%; 55.1%-99.2%). The high efficacy of CAB LA in the penile transmission model supports extending the clinical advancement of CAB LA preexposure prophylaxis to heterosexual men., (© Published by Oxford University Press for the Infectious Diseases Society of America 2020.)
- Published
- 2020
- Full Text
- View/download PDF